Pioneering novel approaches

to increase access for

patients worldwide

Richard Francis, Division Head & CEO Sandoz

Schaftenau, Austria

June 17, 2016

Sandoz

Sandoz

“We discover new ways to

improve and extend

people’s lives...”

“ ...by pioneering novel

approaches

to help people around

the world access high-

quality healthcare”

This is how we contribute to improving society’s

ability to support growing healthcare needs

Our purpose is to increase

access for patients

Business Use Only1

SandozBusiness Use Only2

...and our

aspiration

is to reach

ONE BILLION

Sandoz reached 520 million

patient lives in 2015

Sandoz

Biosimilars are key to increasing

access to life-saving medicines

Business Use Only3

Oncology

Respiratory

Biosimilars

Anti-infectives

Region growth drivers

OTC

Sandoz FY

2015 sales

Of 11 filings

already

completed2

Q1 2016 cc

growth vs PY

Sandoz

access

drivers

USD

772m6 +50%

1. Including retail business 2. 11th filing expected – infliximab

Sandoz

Biosimilars can play a

transformational role in healthcare

Business Use Only4

€49-98BExpected cumulative savings from

biosimilars 2016-2020 in US+EU51

Generate savings for

healthcare systems

~104% Increase in standard units of

filgrastim in the UK from 2008-2014

(post biosimilar launch)1

Improve patient access

Sandoz is committed to driving access to biosimilars and life-saving medicines

1. IMS Institute for Healthcare Informatics: Delivering on the Potential of Biosimilar Medicines. Date of Report: Mar 2016.